PlainRecalls
FDA Drug Moderate Class II Ongoing

Lorazepam Injection, USP, 2 mg/mL, 25 x 1mL vials/carton, Rx Only, Manufactured by: Hikma Berkeley Heights, NJ 07922, NDC# 0641-6044-25

Reported: August 6, 2025 Initiated: July 22, 2025 #D-0551-2025

Product Description

Lorazepam Injection, USP, 2 mg/mL, 25 x 1mL vials/carton, Rx Only, Manufactured by: Hikma Berkeley Heights, NJ 07922, NDC# 0641-6044-25

Reason for Recall

Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds

Details

Units Affected
382,775 1mL vials
Distribution
Distributed Nationwide in the USA
Location
Cherry Hill, NJ

Frequently Asked Questions

What product was recalled?
Lorazepam Injection, USP, 2 mg/mL, 25 x 1mL vials/carton, Rx Only, Manufactured by: Hikma Berkeley Heights, NJ 07922, NDC# 0641-6044-25. Recalled by Hikma Pharmaceuticals USA Inc.. Units affected: 382,775 1mL vials.
Why was this product recalled?
Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds
Which agency issued this recall?
This recall was issued by the FDA Drug on August 6, 2025. Severity: Moderate. Recall number: D-0551-2025.